Multimodal heart and liver imaging in adults from the Constances cohort
Official title: Multimodal Cardiovascular and Hepatic Population Imaging
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT06906042 · Data updated 2026-11-12
This project uses advanced heart and liver imaging to see if scans can reveal early signs of disease in adults from the Constances population cohort.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 2400 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | September 15, 2025 |
| Main results expected | March 14, 2030 |
| Study ends | March 14, 2033 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT06906042 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (age ≥ 20) who are enrolled in the Constances cohort, have no known cardiovascular or hepatic disease, and can safely undergo MRI.
✕Probably not a fit
People with symptomatic heart or liver disease, significant renal impairment (GFR < 60 mL/min/1.73m2), pregnancy, or MRI contraindications are unlikely to gain benefit from this imaging-focused project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project will create a large linked collection of cardiac and hepatic images and associated health data from Constances cohort participants using MRI, echocardiography and standardized paramedical and medical examinations. Participants are adults without known cardiovascular or liver disease who undergo noninvasive imaging and clinical data collection. The resulting multimodal dataset will be analyzed to distinguish normal aging from early disease and to explore how age, sex, genetics and environment relate to residual individual risk. The effort is observational and centralized at Hôpital Pitié‑Salpêtrière with images linked to existing cohort data for long‑term research.
Why it matters
Potential benefit: If successful, the imaging collection could help clinicians spot early heart and liver changes and improve personalized risk predictions.
How similar studies have gone: Large population imaging initiatives (for example cardiac MRI work in population biobanks) have successfully identified subclinical markers, supporting the value of a multimodal imaging approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participation to the Constances cohort * Age ≥ 20 years * No overt cardiovascular or hepatic disease or related symptoms * No known family or personal genetic disease * Affiliation with a social security scheme or beneficiary of such a scheme. * Agreement to sign the consent Exclusion Criteria: * Renal function impairment with GFR \< 60 mL/min/1.73m2 * Deprived of liberty or persons subject to a legal protection measure (under guardianship or trusteeship) * People with contraindications to MRI (claustrophobia, presence of metallic elements…) * Pregnant or breastfeeding woman (pregnancy urinary test before inclusion for women of childbearing age).
Where it's running
-
Hôpital Pitié-Salpêtrière
Paris, France Recruiting
Study contacts
- Study coordinator: Alban M Redheuil, PU-PH
- Email: alban.redheuil@aphp.fr
- Phone: +33142165545
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of Exercise Snacks on Muscle Size and Strength in Healthy Young Adults
This study tests whether many small workouts throughout the week can build muscle size and improve strength in healthy, untrained young adults compared with the usual twice-weekly workouts.
-
ORX489 safety and dosing in healthy adults ages 18 to 60
This will test whether ORX489 tablets are safe, well tolerated, and how they are processed in the body in healthy men and women aged 18 to 60.
-
ReHIIT Prehabilitation in Healthy Adults
This pilot tests a combined resistance and high‑intensity interval training program to establish baseline physiology in healthy adults before applying findings to cancer patients.
-
Safety and drug levels of a 3‑month naltrexone implant (BICX104) with or without bupropion versus monthly Vivitrol injections
This will test whether a three‑month naltrexone implant (BICX104), given alone or with extended‑release bupropion, is safe and keeps steady drug levels compared with monthly Vivitrol injections in healthy adults.
-
Compare two forms and doses of vonafexor and see if the high dose interacts with other drugs
This test looks at how two doses and two formulations of vonafexor (EYP651 and vonafexor acid) are absorbed and processed in healthy adults and whether the high dose interacts with common medicines.
-
Low-frequency vibrating mat for sleep and daily stress recovery
This test will see if using a low-frequency vibrating mat at home for three weeks improves stress recovery, sleep quality, mood, and attention in healthy adults aged 18-45.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.